Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Multiple myeloma, gammopathies

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset

Leukemia volume 32, pages 1414–1420 (2018)Cite this article

Subjects

Abstract

Solitary plasmacytomas are uncommon plasma cell disorders, which may present as a single bone lesion (P-bone) or extramedullary plasmacytoma (P-EM). There is a paucity of large studies analyzing prognostic factors and outcomes of plasmacytomas. While the treatment of choice is radiation therapy (RT), there is a lack of data evaluating optimal RT dose. In this study, we sought to answer these questions by utilizing the National Cancer Database plasmacytoma data from 2000 to 2011. A total of 5056 patients were included in the study (median age 62 years; range 52–72). To obtain a pure plasmacytoma cohort, potential multiple myeloma patients were excluded from the study (bone marrow involvement, systemic chemotherapy use). P-bone constituted 70% of the patients. The median overall survival (OS) of P-EM was significantly longer than P-bone (132 vs. 85 months), and for soft/connective tissue it was worse than remainder of P-EM (82 vs. 148 months). On multivariable analysis, factors associated with worse OS included older age (≥65), presence of P-bone, and treatment with a radiation dose <40 Gy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992–2004. Br J Haematol. 2009;144:86–94.

    Article  PubMed  Google Scholar 

  2. Thumallapally N, Meshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17:13.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Holland J, Trenkner DA, Wasserman TH, Fineberg B. Plasmacytoma. Treatment results and conversion to myeloma. Cancer. 1992;69:1513–7.

    Article  PubMed  CAS  Google Scholar 

  4. Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, et al. Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer. 2006;6:118.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Knowling MA, Harwood AR, Bergsagel DE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol. 1983;1:255–62.

    Article  PubMed  CAS  Google Scholar 

  6. Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol. 2012;87:647–51.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Weberpals J, Pulte D, Jansen L, Luttmann S, Holleczek B, Nennecke A, et al. Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21st century. Haematologica. 2017;102:e229–e232.

    Article  PubMed  PubMed Central  Google Scholar 

  8. National Comprehensive Cancer Network. Multiple Myeloma (Version 3. 2017). Accessed July 24th, 2017. https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf.

  9. Strobl C, Malley J, Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol Methods. 2009;14:323–48.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717–26.

    Article  PubMed  Google Scholar 

  11. Frassica DA, Frassica FJ, Schray MF, Sim FH, Kyle RA. Solitary plasmacytoma of bone: Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 1989;16:43–48.

    Article  PubMed  CAS  Google Scholar 

  12. Ozsahin M, Tsang RW, Poortmans P, Belkacemi Y, Bolla M, Dincbas FO, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210–7.

    Article  PubMed  Google Scholar 

  13. Sasaki R, Yasuda K, Abe E, Uchida N, Kawashima M, Uno T, et al. Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82:626–34.

    Article  PubMed  Google Scholar 

  14. Tournier-Rangeard L, Lapeyre M, Graff-Caillaud P, Mege A, Dolivet G, Toussaint B, et al. Radiotherapy for solitary extramedullary plasmacytoma in the head-and-neck region: a dose greater than 45 Gy to the target volume improves the local control. Int J Radiat Oncol Biol Phys. 2006;64:1013–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Funding

This research was funded by the Mayo Clinic Division of Hematology funds for the Hematology and Oncology Outcomes Research (HONOR) Group. This publication was also supported by the National Cancer Institute of the National Institutes of Health under Award Number K23CA218742.

Author contributions

GG designed the study, interpreted the data, and wrote the paper with assistance from WIG and SK; ACB, JI, and SF performed statistical analysis; NDS, ALM, AAA, PK, UD, SKH, MAS, FKB, RSG, and RAK critically reviewed the manuscript, and approved the final version

Author information

Author notes

  1. Portions of this study were presented at the 2016 American Society of Hematology and 2017 American Society of Clinical Oncology meetings.

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    Gaurav Goyal, Ariela L. Marshall, Aneel A. Ashrani, Prashant Kapoor, Urshila Durani, Shahrukh K. Hashmi, Mustaqeem A. Siddiqui, Francis K. Buadi, Ronald S. Go, Robert A. Kyle, Shaji Kumar & Wilson I. Gonsalves

  2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

    Adam C. Bartley

  3. Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA

    Shealeigh Funni, Jonathan Inselman & Nilay D. Shah

Authors
  1. Gaurav Goyal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam C. Bartley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shealeigh Funni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan Inselman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nilay D. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ariela L. Marshall
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aneel A. Ashrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Prashant Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Urshila Durani
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shahrukh K. Hashmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mustaqeem A. Siddiqui
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Francis K. Buadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ronald S. Go
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Robert A. Kyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shaji Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Wilson I. Gonsalves
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gaurav Goyal.

Ethics declarations

Conflict of interest

SK has research support for clinical trials from Abbott Laboratories, Amgen Inc.; Celgene Corporation; Janssen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; sanofi-aventis US; and Takeda Pharmaceuticals North America Inc. He serves as a scientific advisor for Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlycoMimetics, Janssen Pharmaceutica Products, LP, sanofi-aventis US, and Takeda Pharmaceuticals North America Inc. The other authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goyal, G., Bartley, A.C., Funni, S. et al. Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia 32, 1414–1420 (2018). https://doi.org/10.1038/s41375-018-0099-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0099-8

This article is cited by

Search

Advanced search

Quick links